ADMA Biologics, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

ADMA Biologics reported adjusted earnings of 22 cents per share for the quarter ended September 30, up from 15 cents a year earlier and above analysts’ 20-cent average expectation. Revenue increased 5.1% to $141.10 million, also exceeding analysts’ $138.19 million expectation.

Confirmed

Global impact / market context

Earnings and revenue above expectations indicate the quarter delivered more profit per share and sales than analysts had forecast. If sustained, stronger results could support the company’s ability to fund operations and investment, while giving investors new evidence to assess its business performance.

Analyst inference

The results were stronger than forecasts, but analyst earnings estimates had declined about 3.7% over three months, and no revisions were made in the latest 30 days. Shares were up 10.8% this quarter but down 39.1% year to date, showing mixed performance.

Confirmed

What to watch

1. Watch whether upcoming results maintain revenue growth and earnings above expectations; sustained improvement would provide evidence that the latest quarter was not a one-off. Analyst inference
2. Analyst estimates had fallen about 3.7% over three months, with no revisions in the last 30 days; check whether forecasts begin rising or continue to weaken. Confirmed
3. Analysts’ average rating was “buy,” and the median 12-month price target was $17.50, about 36.5% above the last close of $11.11; these are expectations, not guarantees. Confirmed

Evidence

• Original source link unavailable